Treatment of juvenile idiopathic arthritis: what's new?
Authors:
- 1 September 2019
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Rheumatology
- Vol. 31 (5) , 428-435
Abstract
Purpose of review: The present review highlights the advances in disease outcome achieved with currently available biologic medications and future perspectives for JIA management. Recent findings: In the last two decades, the management of juvenile idiopathic arthritis (JIA) has been revolutionized by appropriate legislative initiatives, the existence of very large collaborative networks and the increased availability of the novel biologic medications. Summary: A more rational approach to the management of JIA is being fostered by the recent publication of therapeutic recommendations, consensus treatment plans and for a treat-to-target strategy.Keywords
This publication has 72 references indexed in Scilit:
- Long‐Term Safety and Efficacy of Rilonacept in Patients With Systemic Juvenile Idiopathic ArthritisArthritis & Rheumatism, 2013
- Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic ArthritisNew England Journal of Medicine, 2012
- Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic ArthritisNew England Journal of Medicine, 2012
- Rates of malignancy associated with juvenile idiopathic arthritis and its treatmentArthritis & Rheumatism, 2012
- Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritisArthritis & Rheumatism, 2011
- A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)Annals of the Rheumatic Diseases, 2011
- Networking in paediatrics: the example of the Paediatric Rheumatology International Trials Organisation (PRINTO)Archives of Disease in Childhood, 2011
- The safety profile of biologic therapies for juvenile idiopathic arthritisNature Reviews Rheumatology, 2010
- Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trialAnnals of the Rheumatic Diseases, 2007
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentNew England Journal of Medicine, 2001